DYAX CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-04: Form 8-K; Period of report 2009-12-03; Description 8.01 Other Events; Details 8.01.
- 2009-12-03: Form 8-K; Period of report 2009-12-01; Description 8.01 Other Events; Details 8.01.
- 2009-11-25: Form 8-K; Period of report 2009-11-19; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2009-10-28: Form 8-K; Period of report 2009-10-28; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-04 | 8-K | 2009-12-03 | 8.01 Other Events | 8.01 On December 3, 2009, Cubist Pharmaceuticals, Inc. our collaborator and licensee for the development of ecallantide for the mitigation of blood loss during surgery, announced the early closing of enrollment in its Phase 2 program for development of Cubist’s ecallantide product known as CB-500,929, as therapy to reduce bleeding in on-pump cardiac surgery. | a6114386.htm |
| 2009-12-03 | 8-K | 2009-12-01 | 8.01 Other Events | 8.01 On December 1, 2009, Dyax Corp. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. | a6113598.htm |
| 2009-11-25 | 8-K | 2009-11-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a6107885.htm |
| 2009-10-28 | 8-K | 2009-10-28 | 2.02 Results of Operations and Financial Condition | 2.02 On October 28, 2009, Dyax Corp. issued a press release announcing its financial results for the quarter ended September 30, 2009. | a6084979.htm |
| 2009-10-01 | 8-K | 2009-09-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a09-28585_38k.htm |
| 2009-07-22 | 8-K | 2009-07-22 | 2.02 Results of Operations and Financial Condition | 2.02 On July 22, 2009, Dyax Corp. issued a press release announcing its financial results for the quarter ended June 30, 2009. | a6012172.htm |
| 2009-07-01 | 8-K | 2009-07-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On July 1, 2009, Clive Wood, Ph.D. informed Dyax that he will resign from his position as Executive Vice President Discovery Research and Chief Scientific Officer effective July 10, 2009. | a5999148.htm |
| 2009-06-25 | 8-K | 2009-06-24 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders | 1.01 On June 24, 2009, Dyax Corp. (the “Company”) entered into an Underwriting Agreement with Deutsche Bank Securities Inc. (the “Underwriting Agreement”), pursuant to which the Company agreed to offer and sell 7,425,743 shares of its common stock in an underwritten public offering. 3.03 Effective as of June 24, 2009, Dyax Corp. (the “Company”) adopted Amendment No. 1 to its Rights Agreement dated as of June 27, 2001 to permit Federated Investors, Inc., its Affiliates and Associates (“Federated”), to be the beneficial owner of not more than nineteen and ninety-nine one hundredths percent (19.99%) of the Company’s outstanding shares of common stock, provided that Federated, in its filings under the Securities Exchange Act of 1934, as amended, states that the shares (or any beneficial ownership thereof, as the case may be) were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Company and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect or the Board of Directors determines in good faith that such Schedule 13D sufficiently demonstrates the foregoing. | a09-16881_38k.htm |
| 2009-06-24 | 8-K | 2009-06-08 | 8.01 Other Events | 8.01 As previously announced in a press release on June 8, 2009, the U.S. Food and Drug Administration (FDA) has accepted for review Dyax Corp.’s submission in response to the FDA’s March 2009 Complete Response letter which outlined requirements for approval of DX-88 for the treatment of acute attacks of hereditary angioedema (HAE). | a5993439.htm |
| 2009-04-22 | 8-K | 2009-04-22 | 2.02 Results of Operations and Financial Condition | 2.02 On April 22, 2009, Dyax Corp. issued a press release announcing its financial results for the quarter ended March 31, 2009. | a5945473.htm |
| 2009-04-17 | 8-K | 2009-04-17 | 8.01 Other Events | 8.01 As previously disclosed on the Form 8-K filed on October 30, 2008, Dyax Corp. (the “Company” or “Dyax”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Azimuth Opportunity Ltd. (“Azimuth”) dated as of October 30, 2008. | a09-10413_38k.htm |
| 2009-03-31 | 8-K | 2009-03-26 | 8.01 Other Events | 8.01 On March 26, 2009, Dyax Corp. (the “Company”) announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) pertaining to the Company’s Biologic License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE). | a5930323.htm |
| 2009-03-19 | 8-K | 2009-03-19 | 8.01 Other Events | 8.01 The U.S. Food and Drug Administration’s (“FDA”) Center for Drug Evaluation and Research (“CDER”), which is currently conducting a priority review of Dyax’s DX-88 in acute attacks of hereditary angioedema (“HAE”), notified Dyax today that they miscalculated the Company’s Prescription Drug User Fee Act (“PDUFA”) target action date. | a5921890.htm |
| 2009-03-18 | 8-K | 2009-03-18 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01 of this current report on Form 8-K regarding the Loan Agreement is hereby incorporated by reference. 3.02 The information set froth under Item 1.01 of this current report on Form 8-K regarding the Warrant Agreement and the issuance of the Warrants is hereby incorporated by reference. | a5920427.htm |
| 2009-02-25 | 8-K | 2009-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2009, Dyax Corp. issued a press release announcing its financial results for the quarter ended December 31, 2008. | a5903844.htm |
| 2009-02-17 | 8-K | 2009-02-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 11, 2009, the Compensation Committee of the Board of Directors of Dyax Corp. determined the base salaries of Dyax’s principal executive officer, principal financial officer and the current executive officers who are the three other most highly compensated executive officers, also known as the named executive officers, and their target bonus potential for 2009 expressed as a percentage of their respective base salaries. | a5897920.htm |